Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−485.03 USD
−7.13 M USD
8.01 M USD
About ReShape Lifesciences, Inc.
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, the Obalon Balloon System, and the Diabetes Bloc-Stim Neuromodulation device. The firm sells the Lap-Band worldwide and is managed in the following geographical regions: United States, Australia, Europe, and the Rest of World. The company was founded in December 2002 and is headquartered in Irvine, CA.
Related stocks
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of HIND is 14.00 USD — it has decreased by −77.68% in the past 24 hours. Watch ReShape Lifesciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ReShape Lifesciences, Inc. stocks are traded under the ticker HIND.
HIND stock has fallen by −62.45% compared to the previous week, the month change is a −67.35% fall, over the last year ReShape Lifesciences, Inc. has showed a −100.00% decrease.
HIND reached its all-time high on Dec 21, 2018 with the price of 171,580,564,741.35 USD, and its all-time low was 8.16 USD and was reached on Aug 13, 2025. View more price dynamics on HIND chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
HIND stock is 398.97% volatile and has beta coefficient of 1.42. Track ReShape Lifesciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is ReShape Lifesciences, Inc. there?
Yes, you can track ReShape Lifesciences, Inc. financials in yearly and quarterly reports right on TradingView.
ReShape Lifesciences, Inc. is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
HIND net income for the last quarter is −2.63 M USD, while the quarter before that showed 1.47 M USD of net income which accounts for −278.43% change. Track more ReShape Lifesciences, Inc. financial stats to get the full picture.
No, HIND doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 17, 2025, the company has 18 employees. See our rating of the largest employees — is ReShape Lifesciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ReShape Lifesciences, Inc. EBITDA is −6.27 M USD, and current EBITDA margin is −83.01%. See more stats in ReShape Lifesciences, Inc. financial statements.
Like other stocks, HIND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ReShape Lifesciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ReShape Lifesciences, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ReShape Lifesciences, Inc. stock shows the sell signal. See more of ReShape Lifesciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.